Comparative Pharmacology
Head-to-head clinical analysis: ZOFRAN versus ZOFRAN ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZOFRAN versus ZOFRAN ODT.
ZOFRAN vs ZOFRAN ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, thereby inhibiting emesis.
Selective antagonist of serotonin 5-HT3 receptors, blocking serotonin binding in the chemoreceptor trigger zone and gastrointestinal tract, thereby inhibiting emesis.
8 mg orally or intravenously 30 minutes before chemotherapy; may repeat 8 mg orally 8 hours after first dose, then 8 mg orally every 12 hours for 1-2 days.
8 mg orally disintegrating tablet (ODT) 30 minutes before chemotherapy; for prevention of nausea/vomiting, 8 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults; in children (1 month to 12 years), half-life averages 2.5 hours; in elderly (≥75 years), half-life may be prolonged to 5.5 hours. Clinically, repeated dosing every 8 hours maintains antiemetic coverage.
Terminal elimination half-life approximately 3–6 hours in adults; prolonged to 8–15 hours in patients with severe hepatic impairment (Child-Pugh C) due to reduced clearance.
Approximately 5% of the dose is excreted unchanged in urine; the remainder undergoes extensive hepatic metabolism via CYP1A1, CYP1A2, CYP3A4, and flavin-containing monooxygenases, with metabolites excreted in urine (about 44-60% of total clearance) and feces (about 25-45%). Less than 10% is eliminated in bile.
Renal (47% as unchanged drug and metabolites, primarily glucuronide conjugates) and hepatic metabolism; about 25% excreted in feces; less than 10% excreted unchanged in urine.
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)